Recent Developments in Hepatic Drug Oxidation Implications for Clinical Pharmacokinetics

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Clinical Pharmacokinetics

• Publication date

  1990-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2165/00003088-199018030-00004PMID 2182263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on the metabolism of perhexiline in man

  2006cited by this paper
• Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

  2005cited by this paper
• Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

  2004cited by this paper
• Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

  2004cited by this paper
• Clinical significance of the sparteine/debrisoquine oxidation polymorphism

  2004cited by this paper
• Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine

  2004cited by this paper
• The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine

  2004cited by this paper
• Relevance of genetic polymorphism in drug metabolism in the development of new drugs

  2004cited by this paper
• Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

  2004cited by this paper
• Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

  2004cited by this paper
• Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

  2004cited by this paper
• Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

  1990cited by this paper
• Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype

  1989cited by this paper
• In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone

  1989cited by this paper
• Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings

  1989cited by this paper
• Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

  1989cited by this paper
• Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4

  1989cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Substantial rise in sparteine metabolic ratio during haloperidol treatment.

  1989cited by this paper
• Inhibitors of the microsomal oxidation of psychotropic drugs: selectivity and clinical significance.

  1989cited by this paper
• The use of human liver banks in pharmacogenetic research.

  1989cited by this paper
• Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype.

  1989cited by this paper
• The P450 Superfamily: Updated Listing of All Genes and Recommended Nomenclature for the Chromosomal Loci

  1989cited by this paper
• Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

  1988cited by this paper
• Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs

  1988cited by this paper
• The relationship between imipramine metabolism and the sparteine oxidation polymorphism.

  1988cited by this paper
• Is there a genetic factor in flecainide toxicity?

  1988cited by this paper
• Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).

  1988cited by this paper
• Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.

  1988cited by this paper
• Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

  1988cited by this paper
• A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.

  1988cited by this paper
• Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.

  1988cited by this paper
• Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.

  1988cited by this paper
• First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

  1988cited by this paper
• Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

  1988cited by this paper
• In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.

  1988cited by this paper
• Inhibition of desipramine 2‐hydroxylation by quinidine and quinine

  1988cited by this paper
• Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase.

  1988cited by this paper
• Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

  1988cited by this paper
• Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

  1988cited by this paper
• Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.

  1988cited by this paper
• Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

  1987cited by this paper
• Evolution of cytochrome P-450 proteins.

  1987cited by this paper
• High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

  1987cited by this paper
• Cyclosporin-erythromycin interaction in normal subjects.

  1987cited by this paper
• Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

  1987cited by this paper
• The P450 Gene Superfamily: Recommended Nomenclature

  1987cited by this paper
• Drug interaction between propafenone and metoprolol.

  1987cited by this paper
• Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

  1987cited by this paper
• The influence of enzyme induction on polymorphic sparteine oxidation.

  1986cited by this paper
• Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver.

  1986cited by this paper
• Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.

  1986cited by this paper
• Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.

  1986cited by this paper
• Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

  1986cited by this paper
• Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype

  1986cited by this paper
• Oxidation of quinidine by human liver cytochrome P-450.

  1986cited by this paper
• Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

  1986cited by this paper
• The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

  1986cited by this paper
• Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

  1986cited by this paper
• Sparteine oxidation is practically abolished in quinidine-treated patients.

  1986cited by this paper
• Metoprolol and debrisoquin metabolism in nigerians: Lack of evidence for polymorphic oxidation

  1986cited by this paper
• Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

  1986cited by this paper
• Sparteine oxidation polymorphism: a family study.

  1986cited by this paper
• Identification of an inducible form of cytochrome P-450 in human liver.

  1985cited by this paper
• Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation

  1985cited by this paper
• Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

  1985cited by this paper
• Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

  1985cited by this paper
• A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

  1985cited by this paper
• Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

  1985cited by this paper
• Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

  1985cited by this paper
• Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.

  1985cited by this paper
• In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

  1985cited by this paper
• Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.

  1985cited by this paper
• Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin

  1985cited by this paper
• Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

  1985cited by this paper
• Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

  1985cited by this paper
• Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

  1984cited by this paper
• Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

  1984cited by this paper
• Relationship of N‐demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism

  1984cited by this paper
• Debrisoquine‐type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation

  1984cited by this paper
• Hepatic Monooxygenase Activities in Subjects With a Genetic Defect in Drug Oxidation

  1983cited by this paper
• Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

  1983cited by this paper
• Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation

  1983cited by this paper
• The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

  1983cited by this paper
• Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.

  1983cited by this paper
• Influence of oxidation polymorphism on phenformin kinetics and dynamics

  1983cited by this paper
• The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

  1983cited by this paper
• Genetically determined oxidation capacity and the disposition of debrisoquine.

  1983cited by this paper
• Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.

  1983cited by this paper
• Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.

  1983cited by this paper
• In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.

  1982cited by this paper
• Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

  1982cited by this paper
• HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION

  1982cited by this paper
• E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation

  1981cited by this paper
• Drug metabolism in human liver in vitro: Establishment of a human liver bank

  1980cited by this paper
• Drug treatment : principles and practice of clinical pharmacology and therapeutics

  1980cited by this paper
• Interindividual differences in amitriptyline demethylation

  1980cited by this paper
• Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.

  1980cited by this paper
• A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

  1980cited by this paper
• Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

  1979cited by this paper

• Significant effects of mixed cations on the morphology and photochemical activities of alkali-metal-antimony (Na,K)Sb3O7.

  2023cites this paper
• Drug Interactions and Adverse Effects

  2015cites this paper
• Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland

  2015cites this paper
• Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence?

  2014cites this paper
• Neurobiology, pharmacokinetics and pharmacodynamics of drug abuse

  2013cites this paper
• A cooperative computational and experimental investigation on electrochemical behavior of metoprolol and its voltammetric determination

  2013cites this paper
• Gibt es prädiktive Parameter für das Ansprechen auf Duloxetin in der Behandlung der Belastungsharninkontinenz

  2012cites this paper
• Simultaneous determination of metoprolol and α-hydroxymetoprolol in human plasma using excitation-emission matrix fluorescence coupled with second-order calibration methods.

  2012cites this paper
• UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO W P OZNANIU KATEDRA I ZAKËAD FARMACJI KLINICZNEJ I BIOFARMACJI PRACOWNIA FARMAKOGENETYKI DOŚWIADCZALNEJ

  2010cites this paper
• Farmacoepidemiología de psicofármacos empleados en la práctica pediátrica en el Servicio de Psiquiatría Infantil del Hospital General de Durango, México

  2010cites this paper
• The genetic bases of inter- and intrastrain differences in CYP2D-dependent drug metabolism in rats

  2009cites this paper
• Actual and potential drug interactions associated with methadone.

  2008cites this paper
• Pharmacogenetics: part I: Perspective. 1992.

  2007cites this paper
• Pharmacogenetics: Part I

  2007cites this paper
• Understanding the essentials of drug interactions: a potential need for safe and effective use of drugs.

  2007cites this paper
• Pharmacogenetics: part II: Perspective. 1992.

  2007cites this paper
• El apoyo del citocromo P450 (CYP2D6) en el uso de medicamentos antipsicóticos

  2007cites this paper
• [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].

  2007cites this paper
• Flecainide for the treatment of chronic neuropathic pain: a Phase II trial

  2007cites this paper
• Venlafaxine induces P‐glycoprotein in human Caco‐2 cells

  2007cites this paper
• Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes

  2006cites this paper
• Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues

  2006cites this paper
• [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].

  2006cites this paper
• Ethnic or Racial Differences Revisited

  2006cites this paper
• Terapêutica Experimental e Clínica na Esquistossomose mansoni

  2005cites this paper
• Role of efflux pumps and metabolising enzymes in drug delivery

  2005cites this paper
• Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism

  2005cites this paper
• The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers

  2005cites this paper
• zur Erlangung des Grades eines Doktors der Medizin dem Fachbereich Medizin der Universität Hamburg vorgelegt von

  2005cites this paper
• Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.

  2005cites this paper
• Oxidative polymorphism of dextromethorphan in a Burundi population

  2004cites this paper
• Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase

  2004cites this paper
• CYP2D6-Phänotypisierung und Bestimmung des Dextromethorphanmetabolismus mittels Hochleistungsflüssigkeitschromatographie

  2003cites this paper
• Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo.

  2003cites this paper
• The study of codeine-gluthetimide pharmacokinetic interaction in rats.

  2003cites this paper
• Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A.

  2003cites this paper
• Pharmacological aspects of nephrotoxicity

  2003cites this paper
• Influence of genetic factors on drug treatment efficacy and safety in cardiovascular diseases

  2003cites this paper
• An amperometric biosensor with human CYP3A4 as a novel drug screening tool.

  2003cites this paper
• The Effect of Sepsis During Parenteral Nutrition on Hepatic Microsomal Function in Rats

  2002cites this paper
• Clinical Pharmacokinetics of Sertraline

  2002cites this paper
• The cytochrome p-450 drug metabolizing enzyme system: an overview of potential clinically important drug interactions.

  2002cites this paper
• Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite

  2002cites this paper
• Pharmacology of 3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Inhibitors (Statins), Including Rosuvastatin and Pitavastatin

  2002cites this paper
• Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain.

  2002cites this paper
• Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs

  2002cites this paper
• The CYP 2 D 6 Humanized Mouse : Effect of the Human CYP 2 D 6 Transgene and HNF 4 on the Disposition of Debrisoquine in the Mouse

  2001cites this paper
• The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

  2001cites this paper
• Pharmacological and toxicological significance of brain cytochromes P450

  2001cites this paper
• Drug Interactions between Psychoactive Agents and Antiepileptic Agents.

  2001cites this paper
• Increasing relevance of pharmacogenetics of drug metabolism in clinical practice

  2001cites this paper
• Clinical Implications of Drug Interactions with Coxibs

  2001cites this paper
• Agony and ecstasy: a review of MDMA effects and toxicity

  2000cites this paper
• Drug Interactions with Cisapride

  2000cites this paper
• Molecular cloning and characterization of three novel cytochrome P450 2D isoforms, CYP2D20, CYP2D27, and CYP2D28 in the Syrian hamster (Mesocricetus auratus).

  2000cites this paper
• The Implications and Management of Drug Interactions with Itraconazole, Fluconazole and Terbinafine

  2000cites this paper
• Pindolol Augmentation of Antidepressants: A Review and Rationale

  2000cites this paper
• Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.

  1999cites this paper
• Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes.

  1999cites this paper
• Polymorphic Cytochromes P450 and Drugs Used in Psychiatry

  1999cites this paper
• Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

  1999cites this paper
• Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results.

  1999cites this paper
• Vincristine pharmacokinetics after repetitive dosing in children

  1999cites this paper
• Pharmacogenetics in the practice of laboratory medicine.

  1999cites this paper
• Chirality and Drugs Used in Psychiatry: Nice to Know or Need to Know?

  1999cites this paper
• Absence of Effect of Stimulants on the Pharmacokinetics of Desipramine in Children

  1999cites this paper
• Depression in Epilepsy: Etiology, Phenomenology, and Treatment

  1999cites this paper
• Antidepressant Drugs and Seizure Susceptibility: From In Vitro Data to Clinical Practice

  1999cites this paper
• SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment

  1998cites this paper
• Psychopharmacology of ADHD: children and adolescents.

  1998cites this paper
• Update: Clinically Significant Cytochrome P‐450 Drug Interactions

  1998cites this paper
• A sensitive assay of metoprolol and its major metabolite alpha-hydroxy metoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detection.

  1998cites this paper
• In vitro approaches to predicting drug interactions in vivo.

  1998cites this paper
• Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2.

  1998cites this paper
• Principles of drug dosing in renal failure

  1998cites this paper
• Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics

  1998cites this paper
• [Pharmacokinetics and relative bioavailability of opipramol in the new INSIDON--sustained release preparation].

  1998cites this paper
• Central nervous system tuberculosis after resolution of miliary tuberculosis.

  1998cites this paper
• Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.

  1998cites this paper
• Metabolism of xenobiotics in the central nervous system: implications and challenges.

  1998cites this paper
• Pharmakokinetik und relative Bioverfügbarkeit von Opipramol aus einem INSIDON®-Dragée

  1998cites this paper
• Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.

  1997cites this paper
• Cytochrome P450 in the metabolism of xenobiotics and drug-drug interactions

  1997cites this paper
• [Effect of antidepressant drugs on cytochrome P-450 isoenzymes and their clinical relevance: differential profile].

  1997cites this paper
• [Genetic polymorphism of drug metabolizing enzymes].

  1997cites this paper
• Drug Interactions with Agents Used in the Treatment of CNS Disorders

  1997cites this paper
• Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes.

  1997cites this paper
• Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County.

  1997cites this paper
• Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

  1997cites this paper
• Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations.

  1997cites this paper
• Effects of Other Pharmacological Agents on Thyroid Function

  1997cites this paper
• Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.

  1997cites this paper
• Metabolic disposition of lansoprazole in relation to the S‐mephenytoin 4′‐hydroxylation phenotype status

  1997cites this paper
• Stereoselective metabolism of rac-mexiletine by the fungus Cunninghamella echinulata yields the major human metabolites hydroxymethylmexiletine and p-hydroxymexiletine.

  1997cites this paper
• Novel Approaches to Drug Delivery in Critical Care

  1997cites this paper
• Brain microsomal metabolism of phencyclidine in male and female rats.

  1997cites this paper
• Metabolism of phencyclidine by human liver microsomes.

  1997cites this paper
• Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County

  1997cites this paper
• Treating Depression: Potential Drug Interactions

  1997cites this paper
• Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.

  1997influential citation